- Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
- In conjunction with the complete response, Larimar is proposing a Phase 2, four-week dose exploration study in Friedreich’s ataxia (FA) patients as CTI-1601’s next clinical trial
- Cash and marketable debt securities at June 30, 2022 of $54.9 million provides projected cash runway through the third quarter of 2023
Read the Full article here